Home News Covid-19

Pfizer vaccine for Covid-19 on track for regulatory review in October

Bloomberg
Bloomberg8/21/2020 02:48 PM GMT+08  • 3 min read
Pfizer vaccine for Covid-19 on track for regulatory review in October
Pfizer Inc. and BioNTech SE said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Pfizer Inc. and BioNTech SE said the Covid-19 vaccine they are jointly developing is on track to be submitted for regulatory review as early as October, as they released additional data from an early-stage study.

The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. The companies are continuing to analyze data from the Phase 1 trials in the US and Germany, they said in a statement.

The confirmation of their October goal, first announced last month, helped lift S&P 500 futures briefly on Friday as part of a drumbeat of positive news on inoculation efforts that have the potential to end the threat of damaging lockdowns.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.